Payment overview · 2025
General Payments
$112.16
7 reported records · 4 companies
Healthcare provider profile · identity verified
Charles Tran, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1396159836
Verified facts
What the public records show
CMS Open Payments records show Charles Tran, M.D. received $112.16 in general payments during 2025 across 7 reported records.
PFIZER INC. accounted for 55.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.33 | 55.6% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.45 | 18.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.83 | 14.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.55 | 12.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $112.16 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.33 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $62.33 | 4 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 656 | 180 |
| Lisinopril | Lisinopril | 331 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 304 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 288 | 79 |
| Losartan Potassium | Losartan Potassium | 242 | 65 |
| Omeprazole | Omeprazole | 176 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 46 |
| Metformin Hcl Er | Metformin Hcl | 159 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 41 |
| Alprazolam | Alprazolam | 134 | 36 |
| Trazodone Hcl | Trazodone Hcl | 132 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 30 |
| Tramadol Hcl | Tramadol Hcl | 115 | 35 |
| Eliquis | Apixaban | 108 | 26 |
| Furosemide | Furosemide | 108 | 37 |
| Meloxicam | Meloxicam | 106 | 39 |
| Gabapentin | Gabapentin | 104 | 36 |
| Simvastatin | Simvastatin | 104 | 31 |
| Sertraline Hcl | Sertraline Hcl | 100 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 99 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 30 |
| Metformin Hcl | Metformin Hcl | 92 | 27 |
| Carvedilol | Carvedilol | 85 | 25 |
| Montelukast Sodium | Montelukast Sodium | 84 | 26 |
| Mounjaro | Tirzepatide | 84 | 14 |
| Alendronate Sodium | Alendronate Sodium | 75 | 25 |
| Atenolol | Atenolol | 70 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 17 |
| Mirtazapine | Mirtazapine | 65 | 21 |
| Glipizide Er | Glipizide | 64 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 17 |
| Bupropion Xl | Bupropion Hcl | 60 | 22 |
| Famotidine | Famotidine | 59 | 19 |
| Ezetimibe | Ezetimibe | 58 | 17 |
| Azelastine Hcl | Azelastine Hcl | 53 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 20 |
| Allopurinol | Allopurinol | 49 | 15 |
| Jardiance | Empagliflozin | 47 | 12 |
| Potassium Chloride | Potassium Chloride | 47 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Diazepam | Diazepam | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 13 |
| Donepezil Hcl | Donepezil Hcl | 43 | 11 |
| Prednisone | Prednisone | 43 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 11 |
| Synthroid | Levothyroxine Sodium | 41 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 21 |
| Azithromycin | Azithromycin | 38 | 34 |
| Lorazepam | Lorazepam | 38 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 32 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 36 | 36 |
| Finasteride | Finasteride | 36 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 19 |
| Fluconazole | Fluconazole | 34 | 16 |
| Spironolactone | Spironolactone | 34 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Cefdinir | Cefdinir | 29 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Levoxyl | Levothyroxine Sodium | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $112.16 · 7 records | PFIZER INC. | INCEPTIV, JARDIANCE, NURTEC ODT, QULIPTA, UBRELVY, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error